GANX: SEC Form 8-K filed by Gain Therapeutics Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for GANX
Across the 25 sessions after earlier GANX headlines, the stock closed higher 11 times and lower 13 times, with a median move of 3.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | GANX | SPY |
|---|---|---|---|
| Oct 13, 2026 | Sibylla Biotech Appoints Usman Azam CEO, Gianluca Fuggetta CFO, and Expands Executive Team to Drive Transition to Clinic | -10.2% | -0.0% |
| Oct 8, 2026 | Gain Therapeutics to Attend the 2026 Maxim Growth Summit | -3.3% | -0.4% |
| Oct 1, 2026 | Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration | -0.6% | +0.2% |
| Sep 30, 2026 | Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders | +3.0% | -0.2% |
| Sep 17, 2026 | Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference | +3.5% | +1.1% |
| Aug 25, 2026 | Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference | -4.7% | +0.3% |
Quantisnow market dataNASDAQ
GANX
Gain Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Get push alerts for GANX
Full GANX profile on Quantisnow Follow GANX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time